Palmoplantar pustulosis
Drug research and approvals for palmoplantar pustulosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 8 studies of palmoplantar pustulosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 9 drug trials for it since 2013.
- Recruiting worldwide: 8
- Trials authorized in Canada: 9
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗- Picankibart in Palmoplantar PustulosisNCT07552454 · Not applicable · Xijing Hospital · starts Apr 15, 2026
- Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar PustulosisNCT07503652 · Phase 4 · First Hospital of China Medical University · starts Mar 1, 2026
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisNCT07219420 · Phase 3 · UCB Biopharma SRL · starts Nov 14, 2025
- A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the…NCT07270003 · Not applicable · Xijing Hospital · starts Oct 1, 2025
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to…NCT07013201 · Phase 2 · LEO Pharma · starts Sep 11, 2025
- Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)NCT06231381 · Phase 2 · Shanghai Huaota Biopharmaceutical Co., Ltd. · starts Feb 29, 2024
- Collection of Samples From Subjects With Various Skin Conditions and Healthy VolunteersNCT05994976 · Not reported · Innovaderm Research Inc. · starts Oct 17, 2023
- International Rare And Severe Psoriasis Expert NetworkNCT04359394 · Not reported · University Hospital, Basel, Switzerland · starts Sep 22, 2021
Trials Authorized in Canada
Newest first; search them all in Canada trials| Sep 23, 2026 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of sonelokimab in participants with palmoplantar…SONELOKIMAB | MOONLAKE IMMUNOTHERAPEUTICS AG | Ongoing |
| Oct 21, 2025 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in…BIMEKIZUMAB | UCB | Ongoing |
| May 8, 2025 | A proof-of-concept phase 2a, double-blind, 2-arm trial to investigate efficacy and safety of twice daily delgocitinib cream 20 mg/g compared with cream vehicle…DELGOCITINIB | LEO Pharma | Ongoing |
| Nov 17, 2021 | A randomized, double-blind, placebo-controlled, dose ranging phase 2 study to evaluate the efficacy and safety of rist4721 in subjects with palmoplantar…RIST4721 | ARISTEA THERAPEUTICS INC | Ongoing |
| May 28, 2020 | An open-label, single arm, long term trial of spesolimab treatment in patients with palmoplantar pustulosis (ppp) who have completed previous bi spesolimab…SPESOLIMAB (BI 655130) | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Closed |
| Jun 19, 2019 | Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of bi…BI 655130 | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Ongoing |
| Mar 20, 2019 | A phase II, randomized, placebo-controlled, double-blind, multiple dose study to evaluate the efficacy and safety of anb019 in subjects with palmoplantar…ANB019 | ANAPTYSBIO INC | Closed |
| Nov 30, 2018 | A randomized, double-blind, placebo-controlled, phase 2a study to evaluate the efficacy and safety of rist4721 in subjects with palmoplantar pustulosisRIST4721 | ARISTEA THERAPEUTICS INC | Closed |
| Mar 28, 2017 | Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety,tolerability, pharmacokinetics and pharmacogenomics…BI 655130 | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA